Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details.
- Share Price: 1621.10 pence per Share.
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Dividend Payment Date: April 9, 2015.
Material Changes
The filing does not report material changes to financial performance or operations compared to prior periods. It details specific share acquisitions by the following individuals:
- Sir Andrew Witty (Director): Acquired 4,611 Ordinary Shares.
- Lady C Witty (Connected Person): Acquired 2,223 Ordinary Shares.
- Mr I W Whyte (Connected Person): Acquired 392 Ordinary Shares.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity.
Investor Verification Checklist
- Verify the total number of shares acquired by directors and connected persons on April 13, 2015.
- Confirm the share price of 1621.10 pence used for the dividend re-investment.
- Review the dividend payment date of April 9, 2015, to understand the timing of the re-investment.